Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| IRWD | IRONWOOD PHARMACEUTICALS INC | 2026-03-02 19:58:52 | 3.55 | -0.02 | -0.56 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IRWD | 0001446847 | IRONWOOD PHARMACEUTICALS INC | US46333X1081 | 549300PC8MR6QHH6P296 | 043404176 | Nasdaq | 2834 | Pharmaceutical Preparations | 1231 | DE | 100 SUMMER STREET, SUITE 2300 | BOSTON | MA | 02110 | UNITED STATES | US | 617-621-7722 | 100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110 | 100 SUMMER STREET, SUITE 2300, BOSTON, MA, 02110 | — | — | 1998 | — | — | http://ironwoodpharma.com/ | 916,974,495 | 162,678,647 | 162,678,647 | Ironwood Pharmaceuticals, Inc. is a publicly traded pharmaceutical company. It was originally called Microbia, Inc. Microbia was founded by postdocs from the lab of Gerald Fink at the Whitehead Institute to commercialize approaches that had been developed in the lab to improve industrial fermentation of fungi, to genetically engineer them to produce secondary metabolites more efficiently or to produce new ones as leads for drug discovery or as products for use in industry, and to identify drug targets in fungi for antifungal drug discovery. In 2002 the company hired John Talley to lead their antifungal drug discovery efforts, which at the time were focused on identifying small molecules that could inhibit fungal invasins, along with Mark Currie who had also worked at Searle division of Monsanto with Talley, and then had gone to Sepracor, and also Richard Bailey, who had run Monsanto's nutritional business. Currie directed the efforts that led to the discovery of linaclotide, which was based on an enterotoxin produced by some strains of Escherichia coli that cause traveler’s diarrhea. | 2026-02-26 18:27:48 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 102,692,312 | -814,282,183 | -88.801 | 163,058,316 | 1,248,884 | 0.7718 |
| 2024 | 916,974,495 | -548,644,924 | -37.4343 | 161,809,432 | 5,280,784 | 3.3737 |
| 2023 | 1,465,619,419 | -89,726,872 | -5.7689 | 156,528,648 | 2,370,602 | 1.5378 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Andrew Davis | Chief Business Officer, Senior Vice President | 2024 | 470,192 | 0 | 2,378,745 | 0 | 33,795 | 2,882,732 |
| John Minardo | Chief Legal Officer, Secretary, Senior Vice President | 2024 | 531,745 | 0 | 1,982,262 | 167,500 | 18,225 | 2,699,731 |
| Thomas Mccourt | Chief Executive Officer | 2024 | 867,568 | 0 | 4,722,733 | 455,473 | 37,857 | 6,083,631 |
| Sravan Emany | Chief Financial Officer, Chief Operating Officer, Senior Vice President | 2024 | 575,067 | 0 | 2,378,745 | 0 | 14,938 | 2,968,751 |
| Michael Shetzline | Chief Medical Officer, Senior Vice President | 2024 | 557,572 | 0 | 1,982,262 | 180,904 | 18,225 | 2,738,962 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 100 |
| 2024 | 253 |
| 2023 | 267 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 296,151,000 | 351,410,000 | 442,735,000 |
| Cost Of Revenue | — | — | — |
| Gross Profit | — | — | — |
| Research And Development Expenses | 95,136,000 | 111,421,000 | 116,085,000 |
| General And Administrative Expenses | 82,256,000 | 144,272,000 | 158,314,000 |
| Operating Expenses | 197,649,000 | 258,286,000 | 1,388,165,000 |
| Operating Income | 98,502,000 | 93,124,000 | -945,430,000 |
| Net Income | 24,017,000 | 880,000 | -1,002,239,000 |
| Earnings Per Share Basic | 0.15 | 0.01 | -6.45 |
| Earnings Per Share Diluted | 0.15 | 0.01 | -6.45 |
| Weighted Average Shares Outstanding Basic | 161,842,000 | 159,083,000 | 155,435,000 |
| Weighted Average Shares Outstanding Diluted | 162,983,000 | 160,084,000 | 155,435,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 215,456,000 | 88,559,000 | 92,154,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 46,700,000 | 81,900,000 | 129,100,000 |
| Inventories | — | — | — |
| Non Trade Receivables | — | — | — |
| Other Assets Current | — | — | — |
| Total Assets Current | 274,178,000 | 182,368,000 | 233,288,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | 3,408,000 | 4,495,000 | 5,585,000 |
| Other Assets Non Current | 4,502,000 | 5,923,000 | 3,608,000 |
| Total Assets Non Current | 122,723,000 | 168,540,000 | 237,785,000 |
| Total Assets | 396,901,000 | 350,908,000 | 471,073,000 |
| Accounts Payable | 2,898,000 | 2,127,000 | 7,830,000 |
| Deferred Revenue | 1,107,000 | 2,032,000 | 2,600,000 |
| Short Term Debt | — | 3,000,000 | 203,750,000 |
| Other Liabilities Current | 927,000 | 521,000 | 1,244,000 |
| Total Liabilities Current | 242,218,000 | 38,846,000 | 276,101,000 |
| Long Term Debt | 199,680,000 | 198,988,000 | 198,309,000 |
| Other Liabilities Non Current | 21,648,000 | 17,105,000 | 28,415,000 |
| Total Liabilities Non Current | — | — | — |
| Total Liabilities | — | — | — |
| Common Stock | 163,000 | 160,000 | 156,000 |
| Retained Earnings | -1,673,718,000 | -1,697,735,000 | -1,698,615,000 |
| Accumulated Other Comprehensive Income | -1,060,000 | 923,000 | -3,031,000 |
| Total Shareholders Equity | -261,835,000 | -301,335,000 | -346,295,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 1,100,000 | 1,200,000 | 1,200,000 |
| Share Based Compensation Expense | 17,250,000 | 29,850,000 | 32,005,000 |
| Other Non Cash Income Expense | -89,000 | -75,000 | — |
| Change In Accounts Receivable | -35,148,000 | -47,236,000 | -924,000 |
| Change In Inventories | — | — | — |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -447,000 | 854,000 | 319,000 |
| Change In Accounts Payable | 6,201,000 | -20,208,000 | 12,380,000 |
| Change In Other Liabilities | — | — | — |
| Cash From Operating Activities | 127,044,000 | 103,549,000 | 183,427,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 34,000 | 142,000 | 273,000 |
| Acquisition Of Business | — | — | — |
| Other Investing Activities | — | — | — |
| Cash From Investing Activities | -34,000 | -142,000 | -1,026,318,000 |
| Tax Withholding For Share Based Compensation | — | 737,000 | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | — |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | — | 150,000,000 | 400,000,000 |
| Repayment Of Long Term Debt | — | — | — |
| Other Financing Activities | 216,000 | 11,013,000 | 6,357,000 |
| Cash From Financing Activities | 216,000 | -106,970,000 | 277,160,000 |
| Change In Cash | 126,897,000 | -3,595,000 | -565,784,000 |
| Cash At End Of Period | 215,456,000 | 88,559,000 | 92,154,000 |
| Income Taxes Paid | 3,543,000 | 8,408,000 | 9,945,000 |
| Interest Paid | 30,333,000 | 32,563,000 | 13,552,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | 0.15 | 0.01 | -6.45 |
| Price To Earnings Ratio | 22.4667 | 443 | -1.7736 |
| Earnings Growth Rate | 1,400 | -100.155 | -670.7965 |
| Price Earnings To Growth Ratio | 0.016 | -4.4231 | 0.0026 |
| Book Value Per Share | 0.9558 | 1.9616 | 1.2544 |
| Price To Book Ratio | 3.526 | 2.2583 | 9.1202 |
| Ebitda | 61,406,000 | 43,522,000 | -969,465,000 |
| Enterprise Value | 529,631,540 | 818,166,690 | 2,088,081,400 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | -0.7626 | -0.6703 | -1.161 |
| Capital Expenditures | 13,000 | 110,000 | 497,000 |
| Free Cash Flow | 127,031,000 | 103,439,000 | 182,930,000 |
| Return On Equity | -0.0917 | -0.0029 | 2.8942 |
| One Year Beta | 0.9418 | 0.4603 | 0.7335 |
| Three Year Beta | 0.7725 | 0.5365 | 0.587 |
| Five Year Beta | 0.6584 | 0.6215 | 0.7056 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| Silver Ronald | Principal Accounting Officer | 2026-02-24 | 12,621 | D | 252,636 |
| Martini Gregory S. | Chief Financial Officer | 2026-02-24 | 11,457 | D | 160,601 |
| MCCOURT Thomas A | Director, Chief Executive Officer | 2026-02-24 | 103,526 | D | 1,489,002 |
| Gaskins Tammi L | Chief Commercial Officer | 2026-02-24 | 11,239 | D | 213,738 |
| Shetzline Michael | SVP, CMO, Head-Res&Drug | 2026-02-24 | 17,012 | A | 521,425 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| DGS Capital Management, LLC | 2025-12-31 | 35,132 | 10,425 | 3.37 |
| Sunbelt Securities, Inc. | 2025-12-31 | 1,496 | 444 | 3.3694 |
| Invesco Ltd. | 2025-12-31 | 1,513,867 | 449,219 | 3.37 |
| NewEdge Advisors, LLC | 2025-12-31 | 19,522 | 5,793 | 3.3699 |
| MACKENZIE FINANCIAL CORP | 2025-12-31 | 38,366 | 11,544 | 3.3235 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| Lazard Active ETF Trust | 2025-12-31 | Lazard US Systematic Small Cap Equity ETF | SYZ | 32,774 | 110,448.38 | 0.1998 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class C | RYCMX | 223 | 751.51 | 0.0089 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class A | RYAKX | 223 | 751.51 | 0.0089 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class H | RYMKX | 223 | 751.51 | 0.0089 |
| RYDEX DYNAMIC FUNDS | 2025-12-31 | H-Class Shares | RYRSX | 816 | 2,749.92 | 0.005 |